Suresh S. Ramalingam, MD | Authors


Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

April 17, 2019

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in EGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

New Data for EGFR Inhibitors for Lung Cancer

May 31, 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses data presented at the 2014 ASCO Annual Meeting examining EGFR inhibitors for lung cancer.